查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2009200

疼痛管理药物市场规模、份额、趋势和预测：按药物类别、适应症、分销管道和地区划分，2026-2034 年。

Pain Management Drugs Market Size, Share, Trends and Forecast by Drug Class, Indication, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2025年全球疼痛管理药物市场规模为730.4亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以2.23%的复合年增长率成长，到2034年达到907亿美元。目前，北美市场主导地位，预计2025年将占45%的市场。该地区受益于先进的医疗基础设施、完善的保险体系（使患者能够广泛获得各种创新型疼痛治疗方案）、不断增长的老年人口中慢性疼痛疾病的高发率，以及对药物研发的大量投入，所有这些因素共同巩固了疼痛管理药物的市场份额。

全球疼痛管理市场成长的主要驱动力是慢性疼痛疾病（包括关节炎、下背痛和神经病变疼痛）盛行率的不断上升，这些疾病影响全球相当一部分人口。全球人口老化加剧了对有效止痛方案的需求，因为老年人更容易患上退化性肌肉骨骼疾病和术后疼痛。此外，肥胖和糖尿病神经病变等文明病负担的加重也推动了对先进镇痛疗法的需求。经皮贴片和缓释製剂等药物传递技术的不断进步，提高了患者的依从性和治疗效果，从而促进了全球疼痛管理市场的成长。

由于多种因素，美国正崛起为疼痛管理药物市场的重要区域。完善的医疗保健基础设施可支持疼痛相关疾病的早期诊断和治疗，而广泛的保险覆盖范围则使患者能够获得各种疼痛管理疗法。 2025年，美国食品药物管理局（FDA）核准了Vertex Pharmaceuticals公司研发的First-in-Class非鸦片类止痛药Journavx（舒吉三嗪）。该药物为中度至重度急性疼痛患者提供了替代传统鸦片类药物的新选择。此外，美国境内主要企业和研究机构的存在，促进了疼痛管理药物製剂研发的持续创新，确保了旨在提高患者疗效并最大限度减少副作用的新疗法的充足供应。

疼痛管理药物市场趋势：

在向非阿片类药物疗法过渡方面正在取得进展。

由于人们对长期使用鸦片类药物风险的认识不断提高，製药业正经历着向非鸦片类镇痛疗法的显着转变。医疗专业人员和政策制定者正优先开发和推广更安全的镇痛替代疗法，包括非类固醇消炎剂、抗惊厥药以及针对特定疼痛途径的新型生物製药。美国《非阿片类药物成瘾预防法案》（NOPAIN）实施一年后进行的一项调查显示，超过80%的医院和手术中心减少了围手术手术全期阿片类药物的处方量，并在疼痛管理方案中增加了合格的非阿片类治疗方法的使用。这一转变得到了更新的临床指南的支持，这些指南建议将非阿片类药物治疗作为许多疼痛疾病（尤其是慢性肌肉骨骼疼痛和神经病变疼痛）的一线治疗通讯协定。

标靶药物传递技术的进展

标靶药物传递系统的创新正在改变疼痛管理市场，它能够提供更精准、更持久的镇痛效果，同时最大限度地减少全身副作用。经皮贴片、脂质体製剂和植入式药物递送装置作为长期镇痛的首选方法，正日益受到关注。 2025年2月，Aveva药物递送系统公司在美国推出了非专利Fentanyl经皮贴片。本产品采用先进的基质技术，旨在提供持续稳定的镇痛效果，同时也具备防止误用的功能。这些技术能够将活性成分精准、直接释放到疼痛部位，进而减少给药频率，提高患者的治疗顺从性。

数位健康解决方案的整合

数位健康技术与疼痛管理药物疗法的融合正在改变治疗模式，并影响全球疼痛管理药物市场的趋势。行动医疗应用程式和穿戴式装置正与药物介入相结合，提供全面的疼痛监测和管理解决方案。这些数位工具使医疗专业人员能够即时追踪患者的疼痛程度、用药模式和治疗结果，从而根据数据调整治疗方案。 2025年9月，Pier 88 Health和Theranica在中国获得了Nerivio® REN的监管核准，这是一款用于治疗偏头痛的可穿戴设备，可提供处方数位药物。这充分体现了数位疼痛管理技术如何超越传统药物疗法，并获得全球临床认可。远端医疗平台正在扩大服务不足地区患者获得疼痛专科医生服务的管道，并提高复杂疼痛症状患者的诊断和处方笺准确性。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章执行摘要

第四章：引言

第五章：全球疼痛管理药物市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场区隔：依药物类别划分
  • 市场区隔：依指标
  • 市场区隔：依分销通路划分
  • 市场区隔：按地区
  • 市场预测

第六章 市场区隔：依药物类别划分

  • NSAIDs
  • 麻醉剂
  • 抗惊厥药物
  • 偏头痛药物
  • 抗忧郁症
  • 阿片类药物
  • 其他的

第七章 市场区隔：依适应症划分

  • 肌肉骨骼疼痛
  • 手术和创伤性疼痛
  • 癌症疼痛
  • 神经性疼痛
  • 偏头痛
  • 产科疼痛
  • 纤维肌痛引起的疼痛
  • 烧伤疼痛
  • 牙齿/脸部疼痛
  • 儿童痛苦
  • 其他的

第八章 市场区隔：依分销通路划分

  • 医院药房
  • 零售药房
  • 网路药房

第九章 市场区隔：依地区划分

  • 北美洲
  • 欧洲
  • 亚太地区
  • 中东和非洲
  • 拉丁美洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

  • 价格指标
  • 价格结构
  • 利润分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Abbott Laboratories Inc.
    • AbbVie Inc.
    • Bausch+Lomb.
    • Bayer AG
    • Eli Lilly & Company
    • GSK plc
    • Pfizer Inc.
    • Purdue Pharma LP
    • Sanofi SA
    • Viatris Inc
Product Code: SR112026A1330

The global pain management drugs market size was valued at USD 73.04 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 90.70 Billion by 2034, exhibiting a CAGR of 2.23% from 2026-2034. North America currently dominates the market, holding a market share of 45% in 2025. The region benefits from its advanced healthcare infrastructure, comprehensive insurance coverage frameworks facilitating broad access to diverse and innovative pain therapies, a high prevalence of chronic pain conditions among its growing aging population, and substantial pharmaceutical research and development investments, all collectively reinforcing the pain management drugs market share.

The global pain management drugs market is being driven by the rising prevalence of chronic pain disorders, including arthritis, lower back pain, and neuropathic conditions, which affect a substantial portion of the global population. The increasing geriatric demographic worldwide is contributing to a higher demand for effective pain relief solutions, as older adults are more susceptible to degenerative musculoskeletal conditions and postoperative pain. Additionally, the growing burden of lifestyle-related ailments such as obesity and diabetes-related neuropathy is fueling the need for advanced analgesic therapies. Ongoing advancements in drug delivery technologies, including transdermal patches and extended-release formulations, are enhancing patient compliance and therapeutic outcomes, thereby supporting the pain management drugs market growth on a global scale.

The United States has emerged as a major region in the pain management drugs market owing to many factors. The well-developed healthcare infrastructure supports early diagnosis and treatment of pain-related conditions, while extensive insurance coverage facilitates patient access to a broad range of pain management therapies. In 2025, the U.S. Food and Drug Administration approved Journavx (suzetrigine) a first-in-class non-opioid analgesic developed by Vertex Pharmaceuticals offering a novel alternative to traditional opioids for moderate-to-severe acute pain. Furthermore, the presence of leading pharmaceutical companies and research institutions in the country fosters continuous innovation in pain management drug formulations, ensuring a robust pipeline of novel therapeutic agents aimed at improving efficacy and minimizing adverse effects for patients.

PAIN MANAGEMENT DRUGS MARKET TRENDS:

Growing Shift Toward Non-Opioid Therapies

The pharmaceutical industry is witnessing a significant transition toward non-opioid pain management therapies driven by heightened awareness of the risks associated with long-term opioid use. Healthcare providers and policymakers are prioritizing the development and adoption of safer analgesic alternatives, including nonsteroidal anti-inflammatory drugs, anticonvulsants, and novel biologics targeting specific pain pathways. According to reports, survey data following the first year of the U.S. Non-Opioids Prevent Addiction (NOPAIN) Act showed that over 80 % of hospitals and surgical centers reported decreasing perioperative opioid prescribing and increasing use of qualifying non-opioid options in pain protocols. This shift is reinforced by updated clinical guidelines that recommend non-opioid treatments as first-line options for many pain conditions, particularly chronic musculoskeletal and neuropathic pain.

Advancements in Targeted Drug Delivery

Innovations in targeted drug delivery systems are transforming the pain management drugs market outlook by enabling more precise and sustained analgesic effects while minimizing systemic side effects. Transdermal patches, liposomal formulations, and implantable drug delivery devices are gaining traction as preferred methods for administering pain medications over extended periods. In February 2025, Aveva Drug Delivery Systems launched its generic fentanyl transdermal patch in the U.S., using advanced matrix technology designed to provide consistent extended pain relief while incorporating features to deter misuse. These technologies allow for controlled release of active pharmaceutical ingredients directly to the site of pain, reducing the need for frequent dosing and improving patient adherence to treatment regimens.

Integration of Digital Health Solutions

The convergence of digital health technologies and pain management pharmacotherapy is reshaping treatment paradigms and influencing the pain management drugs market trends across the globe. Mobile health applications and wearable devices are being integrated with pharmaceutical interventions to provide comprehensive pain monitoring and management solutions. These digital tools enable healthcare providers to track patient pain levels, medication usage patterns, and treatment outcomes in real time, facilitating data-driven adjustments to therapeutic regimens. In September 2025, Pier 88 Health and Theranica received regulatory approval in China for the Nerivio(R) REN wearable device, a prescribed digital therapeutic for migraine that exemplifies how digital pain technologies are gaining global clinical acceptance beyond traditional drug therapy. Telemedicine platforms are expanding access to pain specialists in underserved regions, improving diagnosis and prescription accuracy for patients with complex pain conditions.

PAIN MANAGEMENT DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Antimigraine Agents
  • Antidepressants
  • Opioids
  • Others

Opioids currently occupy a market share of 35%, which is a prominent category in pain management. Opioids are prescribed for moderate to severe pain conditions, such as postoperative pain, cancer pain, and advanced musculoskeletal diseases. Opioids work by interacting with opioid receptors in the central and peripheral nervous system, thus modulating pain perception. The use of opioids in the healthcare setting continues to be high due to their proven efficacy in the management of acute and chronic pain that is unresponsive to non-opioid options. Long-acting and abuse-deterrent formulations of opioids have been introduced to mitigate concerns about opioid abuse while still providing therapeutic benefits to patients who require chronic pain management. Healthcare professionals are increasingly turning to multimodal therapy that combines opioids with other treatments to provide improved pain relief while minimizing opioid use. Guidelines for opioid prescription continue to be refined to ensure prudent use while providing patients with access to pain management options.

Analysis by Indication:

  • Musculoskeletal Pain
  • Surgical and Trauma Pain
  • Cancer Pain
  • Neuropathic Pain
  • Migraine Pain
  • Obstetrical Pain
  • Fibromyalgia Pain
  • Burn Pain
  • Dental/Facial Pain
  • Pediatric Pain
  • Others

Musculoskeletal pain leads the market with a share of 38%. Musculoskeletal pain encompasses a broad spectrum of conditions affecting bones, joints, muscles, tendons, and ligaments, making it one of the most prevalent pain categories globally. The high demand for medications targeting musculoskeletal pain is driven by the increasing incidence of osteoarthritis, rheumatoid arthritis, lower back pain, and sports-related injuries across diverse demographic groups. Aging populations worldwide are particularly susceptible to degenerative joint diseases and spinal disorders, sustaining consistent demand for effective pharmacological interventions. Treatment protocols for musculoskeletal pain typically involve nonsteroidal anti-inflammatory drugs, muscle relaxants, corticosteroids, and topical analgesics, with biologic therapies gaining prominence for refractory cases. The rising adoption of combination therapies and the development of disease-modifying agents are positively influencing the pain management drugs market forecast for this indication. Rehabilitation-focused treatment strategies that integrate pharmacotherapy with physical therapy are becoming standard practice, enhancing overall patient outcomes and driving sustained demand for targeted musculoskeletal pain medications.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hospital pharmacies account for the largest market share of 55%, as they are the main distribution channel for pain management medications due to their direct link with the healthcare system. These pharmacies handle the distribution of controlled medications such as opioids and anesthetics. They are regulated by the relevant authorities to ensure that patients receive the medication correctly. The main reason for the large market share of hospital pharmacies is that they play a crucial role in the management of acute pain, surgical pain, and pain resulting from chronic illnesses. The hospital pharmacists work in collaboration with pain management teams to ensure that the drug selection and monitoring programs are optimized for individual patients. The rising number of surgeries, trauma cases, and cancer treatments in hospitals continues to drive the market through this distribution channel. The hospital pharmacies also handle formulary and bulk purchases that affect prescribing practices and ensure that patients have access to a wide range of analgesic medications at an affordable cost.

Regional Analysis:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

North America, with a market share of 45%, retaining the leading market position. The region enjoys a well-developed healthcare infrastructure with a strong focus on sophisticated diagnostic facilities, comprehensive insurance coverage, and universal access to both primary and specialty pain management care. The large number of patients with chronic pain conditions such as lower back pain, arthritis, and neuropathies in the region supports strong demand for various analgesic treatments. Well-developed pharmaceutical research infrastructure and the presence of major pharmaceutical companies in the region have helped to ensure steady innovation in pain management products, such as abuse-deterrent opioid formulations and new non-opioid modalities. Government policies to counter opioid abuse have spurred the development and launch of safer pain management products, promoting the concept of multimodal pain management. Reimbursement-friendly policies and government-sponsored pain management programs have also helped to ensure better accessibility to prescription pain management products in the region.

KEY REGIONAL TAKEAWAYS:

UNITED STATES PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The United States represents a significant contributor to the pain management drugs market within North America, supported by the high prevalence of chronic and acute pain conditions across the population. The country possesses a well-established pharmaceutical ecosystem with robust research and development capabilities focused on developing next-generation analgesic therapies. In August 2025, the U.S. FDA approved Tonmya a non-opioid treatment for fibromyalgia-related pain, marking the first new therapy for this chronic pain condition in over 15 years and expanding patient options beyond traditional drugs. Healthcare providers are increasingly adopting evidence-based pain management protocols that integrate pharmacological treatments with complementary and alternative approaches, reflecting the evolving clinical landscape. The regulatory environment has shifted toward encouraging non-opioid alternatives, with expedited approval pathways for novel pain therapeutics that demonstrate improved safety profiles. The growing emphasis on personalized medicine is driving the development of genetic testing tools that help clinicians identify optimal pain medications for individual patients, reducing trial-and-error prescribing. Additionally, the expansion of outpatient pain management clinics and ambulatory surgical centers is diversifying drug distribution channels and improving access for patients in rural and underserved communities.

EUROPE PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The European market for pain management drugs is driven by a complex regulatory environment and well-established national healthcare systems that ensure widespread patient access to analgesic treatments. The region has a large burden of chronic pain disorders such as osteoarthritis, rheumatoid arthritis, and cancer pain, which continues to fuel demand for effective pharmacologic therapies. The European regulatory bodies have established tough guidelines for the use of opioids, thus encouraging the use of non-opioid alternatives and multimodal approaches to pain management. The focus on value-based healthcare in the major European economies is shaping formulary inclusion and encouraging the use of cost-effective generic analgesics in combination with innovative branded therapies. Research organizations and pharmaceutical companies in the region are working together on clinical trials for new pain therapies, including biologic and gene therapies that target specific pain pathways. In addition, the aging population in Western European nations is fueling the burden of degenerative musculoskeletal disorders, thus sustaining demand for long-term pain management strategies and rehabilitation pharmacotherapy.

ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Asia-Pacific pain management drugs market is experiencing significant expansion driven by improving healthcare infrastructure, growing awareness of pain management options, and increasing healthcare expenditure across developing economies. The large and aging population base in countries throughout the region contributes to a rising burden of chronic pain conditions, including osteoarthritis, diabetic neuropathy, and cancer-related pain. Government initiatives aimed at expanding universal health coverage and improving access to essential medications are supporting increased utilization of analgesic therapies. The growing middle-class population with enhanced purchasing power is driving demand for advanced branded pain medications in addition to affordable generic alternatives. The region is also witnessing increased investment in pharmaceutical manufacturing capabilities, enabling local production of pain management drugs and reducing dependence on imports.

LATIN AMERICA PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Latin American pain management drugs market is expanding as healthcare infrastructure development progresses across the region, improving access to diagnostic and therapeutic services for pain management. The growing burden of chronic diseases, including diabetes and cardiovascular conditions, is increasing the prevalence of associated pain disorders that require pharmacological intervention. Government healthcare reforms aimed at expanding medication coverage and reducing out-of-pocket expenses are supporting broader patient access to analgesic therapies. The increasing urbanization across the region is facilitating greater awareness of pain treatment options and improving distribution networks for pharmaceutical products. Local generic drug manufacturers are playing a vital role in expanding access.

MIDDLE EAST AND AFRICA PAIN MANAGEMENT DRUGS MARKET ANALYSIS

The Middle East and Africa pain management drugs market is developing steadily as regional healthcare systems undergo modernization and expansion. Growing government investment in healthcare infrastructure is improving access to pain management services, particularly in urban centers across the region. The increasing prevalence of chronic pain conditions linked to lifestyle changes, aging demographics, and road traffic injuries is driving demand for analgesic medications. International pharmaceutical companies are expanding their presence in the region through strategic partnerships with local distributors. Regulatory frameworks governing controlled substance distribution are evolving, facilitating safer and broader access to essential pain management medications for underserved populations.

COMPETITIVE LANDSCAPE:

The pain management drugs market is characterized by intense competition among established pharmaceutical companies, generic drug manufacturers, and emerging biotechnology firms. Major market players are focusing on expanding their product portfolios through the development of novel analgesic formulations, including abuse-deterrent opioids, non-opioid alternatives, and targeted biologic therapies. Strategic initiatives such as mergers, acquisitions, and licensing agreements are being pursued to strengthen market positions and gain access to innovative drug delivery technologies. Companies are investing heavily in clinical research to advance pipeline candidates through regulatory approval processes, with particular emphasis on drugs addressing unmet medical needs in chronic and neuropathic pain management. Competitive differentiation is being achieved through the development of extended-release formulations, combination therapies, and patient-centric drug delivery systems.

The report provides a comprehensive analysis of the competitive landscape in the pain management drugs market with detailed profiles of all major companies, including:

  • Abbott Laboratories Inc.
  • AbbVie Inc.
  • Bausch + Lomb.
  • Bayer AG
  • Eli Lilly & Company
  • GSK plc
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Sanofi S.A
  • Viatris Inc

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the pain management drugs market?

2. What is the future outlook of the pain management drugs market?

3. What are the key factors driving the pain management drugs market?

4. Which region accounts for the largest pain management drugs market share?

5. Which are the leading companies in the global pain management drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pain Management Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Drug Class
  • 5.5 Market Breakup by Indication
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 NSAIDs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anesthetics
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anticonvulsants
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Antimigraine Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antidepressants
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Opioids
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Musculoskeletal Pain
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Surgical and Trauma Pain
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Cancer Pain
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Neuropathic Pain
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Migraine Pain
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Obstetrical Pain
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Fibromyalgia Pain
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Burn Pain
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast
  • 7.9 Dental/Facial Pain
    • 7.9.1 Market Trends
    • 7.9.2 Market Forecast
  • 7.10 Pediatric Pain
    • 7.10.1 Market Trends
    • 7.10.2 Market Forecast
  • 7.11 Others
    • 7.11.1 Market Trends
    • 7.11.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Europe
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Asia Pacific
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

  • 13.1 Price Indicators
  • 13.2 Price Structure
  • 13.3 Margin Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories Inc.
    • 14.3.2 AbbVie Inc.
    • 14.3.3 Bausch + Lomb.
    • 14.3.4 Bayer AG
    • 14.3.5 Eli Lilly & Company
    • 14.3.6 GSK plc
    • 14.3.7 Pfizer Inc.
    • 14.3.8 Purdue Pharma L.P.
    • 14.3.9 Sanofi S.A
    • 14.3.10 Viatris Inc

List of Figures

  • Figure 1: Global: Pain Management Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pain Management Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pain Management Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 4: Global: Pain Management Drugs Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Pain Management Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Pain Management Drugs Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Pain Management Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Pain Management Drugs Industry: SWOT Analysis
  • Figure 9: Global: Pain Management Drugs Industry: Value Chain Analysis
  • Figure 10: Global: Pain Management Drugs Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Pain Management Drugs (NSAIDs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Pain Management Drugs (NSAIDs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Pain Management Drugs (Anesthetics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Pain Management Drugs (Anesthetics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Pain Management Drugs (Anticonvulsants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Pain Management Drugs (Anticonvulsants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Pain Management Drugs (Antimigraine Agents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Pain Management Drugs (Antimigraine Agents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Pain Management Drugs (Antidepressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Pain Management Drugs (Antidepressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Pain Management Drugs (Opioids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Pain Management Drugs (Opioids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Pain Management Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Pain Management Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Pain Management Drugs (Musculoskeletal Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Pain Management Drugs (Musculoskeletal Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Pain Management Drugs (Surgical and Trauma Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Pain Management Drugs (Surgical and Trauma Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Pain Management Drugs (Cancer Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Pain Management Drugs (Cancer Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Pain Management Drugs (Neuropathic Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Pain Management Drugs (Neuropathic Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Pain Management Drugs (Migraine Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Pain Management Drugs (Migraine Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Pain Management Drugs (Obstetrical Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Pain Management Drugs (Obstetrical Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Pain Management Drugs (Fibromyalgia Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Pain Management Drugs (Fibromyalgia Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Global: Pain Management Drugs (Burn Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Global: Pain Management Drugs (Burn Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Global: Pain Management Drugs (Dental/Facial Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Global: Pain Management Drugs (Dental/Facial Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Global: Pain Management Drugs (Pediatric Pain) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Global: Pain Management Drugs (Pediatric Pain) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Global: Pain Management Drugs (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Global: Pain Management Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Global: Pain Management Drugs Market: Sales through Hospital Pharmacies (in Million USD), 2020 & 2025
  • Figure 48: Global: Pain Management Drugs Market Forecast: Sales through Hospital Pharmacies (in Million USD), 2026-2034
  • Figure 49: Global: Pain Management Drugs Market: Sales through Retail Pharmacies (in Million USD), 2020 & 2025
  • Figure 50: Global: Pain Management Drugs Market Forecast: Sales through Retail Pharmacies (in Million USD), 2026-2034
  • Figure 51: Global: Pain Management Drugs Market: Sales through Online Pharmacies (in Million USD), 2020 & 2025
  • Figure 52: Global: Pain Management Drugs Market Forecast: Sales through Online Pharmacies (in Million USD), 2026-2034
  • Figure 53: North America: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: North America: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Europe: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Europe: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Asia Pacific: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Asia Pacific: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Middle East and Africa: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Middle East and Africa: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Latin America: Pain Management Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Latin America: Pain Management Drugs Market Forecast: Sales Value (in Million USD), 2026-2034

List of Tables

  • Table 1: Global: Pain Management Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pain Management Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Pain Management Drugs Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 4: Global: Pain Management Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Pain Management Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Pain Management Drugs Market Structure
  • Table 7: Global: Pain Management Drugs Market: Key Players